Molecular Analysis and Computational Modeling Reveal Temporally Separable Responses triggered by DENV-Induced Soluble Factors in Endothelial Cells

By integrating in vitro experiments with computational modeling, this study reveals that soluble factors from DENV-infected cells trigger a temporally distinct sequence of inflammatory and reparatory responses in endothelial cells, ultimately driving dysfunction through the upregulation of SNA1, CDH2, IL6, and FN1.

The Gist

The Big Picture: A City Under Siege

Imagine your body's blood vessels as a bustling city. The endothelial cells are the city's security guards and the bricks holding the walls together. Their job is to keep everything tight, secure, and organized so that blood stays inside the pipes and doesn't leak out.

When you get Dengue Fever, the virus attacks this city. But here's the twist: the virus doesn't just smash the walls directly. Instead, it sends out a "distress signal" (soluble factors) that confuses the security guards. This paper investigates what happens to those guards when they receive these confusing signals.

The Discovery: A Two-Act Play

The researchers found that the Dengue virus doesn't just cause one type of damage. It triggers a two-stage drama in the blood vessel cells, like a play with two very different acts.

Act 1: The Panic Room (The Inflammatory Phase)

• Time: Early stage (around 48 hours).
• What happens: The "distress signals" from the virus hit the cells. The cells go into panic mode. They start shouting for help, releasing a flood of alarm bells (inflammatory chemicals like IL-6).
• The Analogy: Imagine a fire alarm going off in a building. Everyone starts running, doors are thrown open, and the security guards are distracted by the noise. The walls become loose and leaky. This is why patients get fevers and why blood vessels start to become "leaky" early in the infection.

Act 2: The Construction Crew (The Repair/Plasticity Phase)

• Time: Later stage (around 120 hours).
• What happens: Once the initial panic subsides, the cells try to fix the mess. But instead of just patching the holes, they start changing their identity. They begin to act like "construction workers" (mesenchymal cells) rather than "security guards."
• The Analogy: The security guards decide to put on hard hats and pick up shovels. They start tearing down the old, tight brick walls to build a new, more flexible structure. While this is meant to be a repair job, it actually makes the walls weaker and more permeable. This is a process called Endothelial-to-Mesenchymal Transition (EndMT).

The Key Insight: The virus causes the cells to lose their "security guard" identity and become "construction workers." This change makes the blood vessels leaky, leading to the severe bleeding and shock seen in dangerous Dengue cases.

The Detective Work: How They Figured It Out

The scientists didn't just guess; they used two powerful tools to solve the mystery:

1. The Microscope (Lab Work): They grew human blood vessel cells in a dish and bathed them in "soup" taken from Dengue-infected cells (but without the actual virus, just the signals). They watched the cells change shape and checked their "ID cards" (genes) to see if they were turning into security guards or construction workers.
2. The Computer Simulation (The Digital Twin): Since biology is messy, they built a computer model (a digital twin of the cell's internal network). They fed the model all the data from the lab.
   • Think of this like a flight simulator. They could crash the plane (delete a gene) or add extra fuel (overexpress a gene) to see what would happen without hurting real people.

The Villains and the Heroes

Using their computer model, they identified the main characters driving this drama:

• The Masterminds (IL-6 and FN1): The model predicted that two specific signals, IL-6 (an alarm bell) and FN1 (a structural glue called Fibronectin), are the bosses running the show. If you stop them, the chaos stops.
• The Potential Heroes (Therapies): The study suggests that if we can block these two villains, we might be able to stop the blood vessels from leaking.
  • Idea: Drugs that block IL-6 (like those used for other autoimmune diseases) or drugs that stabilize the cell walls (like Imatinib, which they tested) could be the "fire extinguishers" needed to save patients with severe Dengue.

Why This Matters

For a long time, doctors thought severe Dengue was just a massive immune system overreaction. This paper adds a new chapter: The cells themselves are changing their identity.

It's like realizing that the reason a dam is breaking isn't just because of the water pressure, but because the bricks decided to turn into sand.

The Takeaway:
Dengue fever causes a temporary but dangerous transformation in our blood vessel cells. They panic first, then they try to rebuild by changing their shape, which accidentally makes them leaky. By understanding this "two-act play," scientists can now look for drugs that specifically stop the cells from changing their identity, potentially saving lives during severe outbreaks.

Technical Summary

1. Problem Statement

Severe Dengue (SD) is a life-threatening complication of Dengue virus (DENV) infection characterized by generalized hemorrhage and vascular leakage. A central feature of SD is endothelial dysfunction, yet the precise molecular mechanisms driving this dysfunction remain elusive.

• The Paradox: SD symptoms often peak during the defervescence stage (when viral load/viremia is declining), suggesting that host-derived soluble factors, rather than direct viral cytopathic effects, drive the pathology.
• The Gap: While previous studies indicated that DENV-induced soluble factors trigger an Endothelial-to-Mesenchymal Transition (EndMT)-like state and increased permeability, the temporal kinetics, the distinction between inflammatory and reparative phases, and the specific molecular networks governing this process were not fully understood.
• Objective: To integrate in vitro transcriptomics with computational modeling to define the temporal dynamics of DENV-induced endothelial alterations and identify key therapeutic targets.

2. Methodology

The study employed a multi-omics and systems biology approach:

• In Vitro Model: Human Microvascular Endothelial Cells (HMEC-1) were treated with CMDV (Conditioned Media from DENV-infected cells, UV-inactivated to remove viral particles but retain soluble factors) and compared against TGF-β1 (a known EndMT inducer) and untreated controls.
• Time Points: Cells were analyzed at 48 hours (early phase) and 120 hours (late phase).
• Experimental Techniques:
  • Immunofluorescence & Microscopy: Quantified protein expression of endothelial markers (VE-cadherin, Occludin) and mesenchymal markers (N-cadherin, Snail).
  • RNA-Seq (Bulk): Performed on HMEC-1 cells to identify Differentially Expressed Genes (DEGs) at both time points.
  • RT-qPCR: Validated key gene expression (SNA1, TWIST1, VIM).
  • Pharmacological Inhibition: Used Imatinib (c-Abl inhibitor) to test reversibility of junctional disruption.
• Computational Modeling:
  • Network Construction: Built a Non-Directed Asynchronous Boolean Network (NDAM-CMDV) using DEGs from 48h and 120h.
  • Data Integration: Merged interactomes from StringDB and literature-derived interactions to define 41 nodes and 99 edges.
  • Simulation: Ran 25,000 asynchronous simulations (100 iterations each) to identify system attractors, robustness, and response to perturbations (knockouts/overexpression).
  • Thresholding: Implemented a first-order decay model to simulate the temporal transition from inflammation to repair.

3. Key Contributions

1. Temporal Decoupling of Responses: The study definitively separates the DENV-induced endothelial response into two distinct phases: an early pro-inflammatory phase (48h) and a late tissue repair/remodeling phase (120h).
2. Partial/Transient EndMT: It characterizes the endothelial response not as a binary, permanent switch to mesenchymal cells, but as a reversible, partial EndMT that facilitates immune recruitment and subsequent repair.
3. Identification of Central Drivers: Through computational centrality analysis, the study identifies IL-6 and Fibronectin (FN1) as the critical "hub" nodes driving the transition and sustaining the pathological state.
4. Predictive Modeling: The development of the NDAM-CMDV model provides a robust in silico framework to predict endothelial behavior under various genetic perturbations, offering a new tool for drug discovery in Dengue.

4. Key Results

A. Phenotypic and Molecular Changes

• Marker Expression: CMDV treatment did not significantly alter endothelial/mesenchymal markers at 48h. However, by 120h, there was a significant downregulation of endothelial markers (VE-cadherin/CDH5, Occludin/OCLN) and upregulation of mesenchymal markers (N-cadherin/CDH2, Snail/SNA1, Vimentin/VIM).
• Imatinib Effect: Treatment with Imatinib partially restored junctional protein expression but failed to fully restore morphological integrity, suggesting cytoskeletal involvement beyond c-Abl inhibition.

B. Transcriptomic Dynamics (RNA-Seq)

• 48 Hours (Inflammatory Phase): CMDV triggered a transient pro-inflammatory response with ~100 DEGs. Key upregulated genes included IL-6, CXCL1, CXCL2, CCL2, and IL-7. This phase is distinct from TGF-β1 treatment, which did not induce these inflammatory markers at this stage.
• 120 Hours (Repair/Remodeling Phase): The response shifted to a massive transcriptional program (~742 DEGs) focused on cell cycle, mitosis, and extracellular matrix (ECM) remodeling. Key genes included MYC, TENM2, COL5A2, and FN1.
• Comparison with TGF-β1: While TGF-β1 induced a direct, linear EndMT, CMDV induced a biphasic response: inflammation first, followed by a repair program that overlaps with TGF-β1-induced remodeling only at the later stage.

C. Network Modeling (NDAM-CMDV)

• Network Topology: The model consists of 41 nodes. Centrality analysis identified IL-6 (highest betweenness and eigenvector centrality) and FN1 as the most influential nodes.
• Simulation Dynamics:
  • Iterations 1–25: Pro-inflammatory nodes (IL-6, CXCLs) are active.
  • Iterations 26–100: Inflammatory nodes decay; reparative/plasticity nodes (FN1, ECM genes) become dominant.
  • Attractors: The system converges to stable states (attractors) involving IL-6, SEMA3A, LCN2, and IL1R2, indicating high system stability.
• Perturbation Analysis:
  • IL-6 Knockout: Abrogated the induction of CCL2, CXCLs, and VCAM1, preventing the inflammatory surge.
  • FN1 Knockout: Disrupted the ECM remodeling and repair phase.
  • Triple Knockout (IL-6, FN1, VCAM1): Completely inhibited the inflammatory response and altered the timing of repair gene activation.
  • FGF2 Overexpression: Modulated the network but did not fully compensate for the loss of IL-6 or FN1.

5. Significance and Implications

• Mechanistic Insight: The study provides a mechanistic explanation for why vascular leakage in Dengue occurs during the defervescence phase: the initial inflammatory surge primes the endothelium, and the subsequent partial EndMT (driven by IL-6 and FN1) leads to junctional weakening and permeability before a repair attempt begins.
• Therapeutic Targets:
  • IL-6 Inhibition: Suggests that IL-6 inhibitors (e.g., Tocilizumab) could attenuate the early inflammatory damage.
  • FN1 Stabilization: Targeting FN1-driven ECM breakdown could preserve vascular integrity.
  • Synergistic Approaches: The model supports combining anti-inflammatory strategies with cytoskeletal stabilizers (like Imatinib) to prevent the transition to a pathological mesenchymal state.
• Broader Relevance: The concept of a "regulated, transient EndMT" may apply to other acute inflammatory conditions involving endothelial dysfunction, such as sepsis.
• Methodological Advance: The successful integration of bulk RNA-seq with asynchronous Boolean modeling demonstrates a powerful workflow for studying complex, time-dependent cellular plasticity where traditional static models fail.

In conclusion, this paper establishes that DENV-induced soluble factors drive a biphasic, reversible endothelial dysfunction mediated by a specific network centered on IL-6 and FN1, offering a new conceptual framework for treating Severe Dengue.